Author: NTIDC-EmpireDD

Gilead’s New Capsid Inhibitor in Early Trials
Post

Gilead’s New Capsid Inhibitor in Early Trials

Gilead’s new capsid inhibitor GS-6207 has started its phase 1b trial with the potential for 3 month dosing. The capsid inhibitor is currently being dosed by a subcutaneous injection but Gilead is attempting to develop a oral formulation of the antiretroviral.

Infectious Disease Medicine
Project

Infectious Disease Medicine

Infectious Diseases physicians are highly trained specialists, having spent 4 years completing medical school training, 3 years completing an Internal Medicine Residency Training Program and a minimum of 2 years of sub-specialty fellowship training in Infectious Diseases Medicine.